Gastric HER2 testing study (GaTHER): An evaluation of gastric/ gastroesophageal junction cancer testing accuracy in Australia

Fox, Stephen B., Kumarasinghe, Marian Priyanthi, Armes, Jane E., Bilous, Michael, Cummings, Margaret C., Farshid, Gelareh, Fitzpatrick, Nicole, Francis, Glenn D., McCloud, Philip I., Raymond, Wendy and Morey, Adrienne (2012) Gastric HER2 testing study (GaTHER): An evaluation of gastric/ gastroesophageal junction cancer testing accuracy in Australia. American Journal of Surgical Pathology, 36 4: 577-582.

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads

Author Fox, Stephen B.
Kumarasinghe, Marian Priyanthi
Armes, Jane E.
Bilous, Michael
Cummings, Margaret C.
Farshid, Gelareh
Fitzpatrick, Nicole
Francis, Glenn D.
McCloud, Philip I.
Raymond, Wendy
Morey, Adrienne
Title Gastric HER2 testing study (GaTHER): An evaluation of gastric/ gastroesophageal junction cancer testing accuracy in Australia
Journal name American Journal of Surgical Pathology   Check publisher's open access policy
ISSN 0147-5185
1532-0979
Publication date 2012-04
Sub-type Article (original research)
DOI 10.1097/PAS.0b013e318244adbb
Volume 36
Issue 4
Start page 577
End page 582
Total pages 6
Place of publication Philadelphia, PA, United States
Publisher Lippincott Williams & Wilkins
Collection year 2013
Language eng
Abstract Trastuzumab provides a survival benefit in patients with human epidermal growth factor receptor 2 (HER2)-amplified/overexpressed advanced gastric and gastroesophageal junction cancers (GC/GJCs). However, the optimal method for testing is unclear. The aim of this study was to assess interlaboratory agreement on HER2 scoring in GC/GJC to aid the development of a robust testing algorithm for diagnostic practice in Australia. Nine laboratories assessed the HER2 status of 100 GC/GJC tissue samples by immunohistochemistry (IHC) and in situ hybridization (ISH) [chromogenic (CISH) or silver (SISH)] using both HER2 copy number and HER2:chr17 (chromosome 17) ratio. Results were compared with reference fluorescence ISH (FISH). Interlaboratory agreement on IHC3+ scoring was good (κ=0.76), and there was good/very good agreement between IHC (positivity defined as IHC3+) and ISH when HER2 copy number was used (κ=0.72 to 0.87). Agreement on CISH/SISH scoring was good/very good when HER2 copy number was used (κ=0.68 to 0.86), and agreement between CISH/SISH and FISH using HER2 copy number was very good (κ=0.88 to 0.91). Agreement was reduced when HER2:chr17 ratio was used. The good agreement for HER2 copy number determined by bright-field ISH suggests that this is the optimal method for testing in GC/GJC cases. An IHC3+ score was strongly predictive of a positive ISH result, although agreement for all IHC scores was only moderate, suggesting that IHC triage before ISH testing would be the most cost-effective strategy. However, because of the unique features of GC/GJC samples and the difficulty of ensuring consistent HER2 staining in the community setting, it is recommended that HER2 status in advanced GC/GJC be determined by both IHC and ISH in the same laboratory.
Keyword Gastric cancer
HER2
Immunohistochemistry
In situ hybridization
Trastuzumab
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: Official 2013 Collection
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 4 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 5 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Access Statistics: 54 Abstract Views, 0 File Downloads  -  Detailed Statistics
Created: Fri, 29 Jun 2012, 14:07:59 EST by Matthew Lamb on behalf of School of Medicine